

Attorney Docket No. <u>249.P2</u> *PATENT* 

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re applica	tion of: Mark W. B	ecker					
Serial No.:	10/785,497	Group No	p.: 1657				
Filed:	February 24, 2004	Examiner	r: Paul C. Martin				
For:	PRODRUGS OF PHOSPHONATE NUCLEOTIDE ANALOGUES AND METHODS FOR SELECTING AND MAKING SAME						
Mail Stop M P.O. Box 14							
	INFORMATIO	N DISCLOSUE	RE STATEMENT (modified)				
List of Sections Forming Part of This Information Disclosure Statement.							
The followin	g sections are being	submitted for this	Information Disclosure Statement:				
1. X	Preliminary Stateme	ents					
2. x	FORM PTO - 1449	- <u>Pages</u>					
3.	Identification of Prio	r Application in Wh	nich Listed Information Was Already Cited.				
		CERTIFICATE (	OF MAILING				
attached or e	nclosed) is being dep	osited on the date s	ement (along with any paper referred to as bein hown below with the United States Postal Service is, P.O. Box 1450, Alexandria, VA 22313-1450.				
	37 CFR 1.8 (a) ient postage as mail	<u>or</u>	37 CFR 1.10 as "Express Mail Post Office to Addressee" Mailing Label No.				
Date:	8/17/01		Donna J. Macedo  (Type or print name of person mailing paper)  (Signature of person mailing paper)				
			/				

## Section 1. Preliminary statements

Applicants submit herewith patents, publications or other information of which they are aware, which they believe may be material to the examination of this application and in respect of which there may be a duty to disclose. To the extent that this submission includes an International Search Report, such Report is submitted to facilitate the Examiner's analysis of the references and not out of any belief that the International Searching Authority's construction of the relevance of the references has any bearing under United States Law.

The filing of this information disclosure statement shall not be construed as a representation that a search has been made (37 CFR 1.97 (g)), an admission that the information cited is, or is considered to be, material to patentability or that no other material information exists.

The filing of this information disclosure statement shall not be construed as an admission against interest in any manner. Notice of January 9, 1992, 1135 O.G. 13-25, at 25.

## Section 3. Identification of Prior Application in Which Listed Information Was Already Cited and for Which No Copies Are Submitted or Need Be Submitted

This application relies, under 35 U.S.C. 120, at least on the earlier filing dates of prior applications:

Serial No.

, filed on

Copies of references are not supplied to the extent that they are found in the file history of the prior application(s). Copies of references that were not supplied in the prior application(s), if any, accompany this paper.

Reg. No. 27,043

Tel. No.: (650) 522-5709

SIGNATURE OF ATTORNEY

Max Hensley

Type or print name of attorney

Gilead Sciences, Inc. 333 Lakeside Drive Foster City, CA 94404

PTO/SB/08B (04-07)

Approved for use through 09/30/2007. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449/PTO	re required to respond to a collection of information unless it contains a valid OMB control number.  Complete if Known		
HEAD STATE OF THE PARTY OF THE	Application Number	10/785,497	
INFORMATION DISCLOSURE	Filing Date	February 24, 2004	
STATEMENT BY APPLICANT	First Named Inventor	Mark W. Becker	
(Use as many sheets as necessary)	Art Unit	1657	
(Use as many sneets as necessary)	Examiner Name	Paul C. Martin	
Sheet 1 of 1	Attorney Docket Number	249.P2	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		http://www.google.com/search. define: blood plasma-Google Search "Definitions of Blood Plasma on the Web" 08/16/2007	
Everniner		Data	

Examiner Date Considered

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.